Effect of systemic therapies or best supportive care after disease progression to both nivolumab and cabozantinib in metastatic renal cell carcinoma: The Meet-Uro 19BEYOND study.
Roviello G, Gambale E, Giorgione R, Santini D, Stellato M, Fornarini G, Rebuzzi SE, Basso U, Bimbatti D, Doni L, Nesi G, Bersanelli M, Buti S, De Giorgi U, Galli L, Sbrana A, Conca R, Carella C, Naglieri E, Pignata S, Procopio G, Antonuzzo L.
Roviello G, et al. Among authors: giorgione r.
Cancer Med. 2022 Aug;11(16):3084-3092. doi: 10.1002/cam4.4681. Epub 2022 Mar 20.
Cancer Med. 2022.
PMID: 35312175
Free PMC article.